MetaCap

Lycia Therapeutics Inc. Company Profile

NASDAQ: LYCAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

33.07+1.30 (+4.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Lycia Therapeutics at a glance

Lycia Therapeutics Inc. (NASDAQ: LYCA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in South San Francisco, CA. Lycia Therapeutics is led by Dr. Aetna Wun Trombley Ph.D. and employs about 31 people. The company's shares have traded publicly since 2026.

At a market capitalization of $1.72 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001806540, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Lycia Therapeutics do?

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases. Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease. Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Business description based on the company's public filings.

Company information

Legal name
Lycia Therapeutics Inc.
Ticker
NASDAQ: LYCA
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Aetna Wun Trombley Ph.D.
Employees
31
Headquarters
400 East Jamie Court, South San Francisco, CA, United States
Phone
(650) 392-3357
IPO year
2026
SEC CIK
0001806540

Companies similar to Lycia Therapeutics

LYCA peer companies
CompanyPrice% ChgMarket capCompare
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs LYCA
REPLReplimune Group Inc.19.07-0.83%$1.81Bvs LYCA
COAGHemab Therapeutics Holdings Inc.39.29-1.43%$1.84Bvs LYCA
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs LYCA
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs LYCA
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs LYCA
ALVOAlvotech4.12-3.96%$1.47Bvs LYCA
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs LYCA

Related